Jump to Content
Jump to Main Navigation
HOME
BROWSE
SUBJECTS
CLINICAL RESOURCES
DRUG INFORMATION
EDUCATION AND TRAINING
PHARMACY PRACTICE
CAREER DEVELOPMENT
AJHP
DRUG INFORMATION
PROFESSIONAL DEVELOPMENT
Sign in
Sign up
SEARCH
Advanced Search
Help
Sign in
Sign up
HOME
BROWSE
SUBJECTS
CLINICAL RESOURCES
DRUG INFORMATION
EDUCATION AND TRAINING
PHARMACY PRACTICE
CAREER DEVELOPMENT
AJHP
DRUG INFORMATION
PROFESSIONAL DEVELOPMENT
SEARCH
Advanced Search
Help
Archive
|
ashp
|
2018
|
08
Preliminary Material
1. Introduction to Anticoagulation Management
2. Warfarin
3. Unfractionated Heparin
4. Low Molecular Weight Heparin and Fondaparinux
5. Parenteral Direct Thrombin Inhibitors
6. Thrombolytic Considerations When Used with Anticoagulants
7. Direct Oral Anticoagulants
8. Anticoagulation Reversal: Part I—Pharmacology of Agents Used for Reversal
9. Anticoagulation Reversal: Part II—Clinical Application
10. Transitions in Care—Periprocedural Bridging and Transitions Between Agents
11. Considerations in Special Populations
12. Venous Thromboembolism Prevention
13. Venous Thromboembolism Treatment
14. Atrial Fibrillation
15. Acute Coronary Syndromes
16. Prosthetic Heart Valves
17. Mechanical Circulatory Support Devices
18. Heparin-Induced Thrombocytopenia
19. Pregnancy
20. Pediatrics
21. Coagulation Laboratory Considerations
22. Thrombophilias
23. Models and Standards of Anticoagulation Care Delivery
24. Regulatory and Practice Resources
Appendix A. Coagulation Cascade
Appendix B. Agents Implicated in Drug-Induced Thromboembolic Diseases
Appendix C. Nutrition Influence on Anticoagulation
Appendix D. Anticoagulants in Management of Ischemic Stroke or Transient Ischemic Attacks
Appendix E. Citrate Anticoagulation
Appendix F. Examples of Available Bleeding Definitions
Appendix G. Types of CNS Hemorrhage
Appendix H. Disseminated Intravascular Coagulation
Appendix I. Nondrug Causes of Thrombocytopenia
Appendix J. Drug-Related Causes of Thrombocytopenia
Appendix K. Examples of Transfusion-Related Reactions
Appendix L. Considerations for Transitioning from aPTT to Anti-Xa to Manage Heparin Therapy
Appendix M. PIONEER AF-PCI
Appendix N. Betrixaban APEX Trial
Index
Preliminary Material
Chapter 1: Introduction to Opioid Conversion Calculations
Chapter 2: Converting Among Routes and Formulations of the Same Opioid
Chapter 3: Converting Among Routes and Formulations of Different Opioids
Chapter 4: Titrating Opioid Regimens: Around the Clock and to the Rescue!
Chapter 5: Transdermal and Parenteral Fentanyl Dosage Calculations and Conversions
Chapter 6: Methadone: A Complex and Challenging Analgesic, But It’s Worth It!
Chapter 7: Patient-Controlled Analgesia and Neuraxial Opioid Therapy
Chapter 8: Calculating Doses from Oral Solutions and Suspensions
Chapter 9: Lagniappe: A Little Something Extra in Conversion Calculations
Glossary
Index
[3.239.59.31]
3.239.59.31
